02317nas a2200277 4500000000100000008004100001260004200042653002500084653001400109653001200123653001200135653002500147100001300172700001400185700001300199700001400212700001300226700001100239700001500250700001300265245016800278856006300446300000900509520150700518022001402025 2025 d c07/2025bSercrisma International S.L.10aImmunohistochemistry10aBiomarker10aADAMTS410aLeprosy10aMycobacterium leprae1 aSoares C1 aGarrido I1 aSoares R1 aVirgili N1 aFachin L1 aRosa P1 aTrombone A1 aBelone A00aADAMTS4 is expressed in different cells and tissues in leprosy skin lesions: A potential biomarker and therapeutic target for leprosy and its reactional phenomena. uhttps://www.hh.um.es/Articles-Proofs/18-959-manuscript.pdf a1-263 a

INTRODUCTION: A disintegrin and metalloproteinase with thrombospondin motifs-4 (ADAMTS4), a metalloproteinase involved in extracellular matrix (ECM) degradation, is implicated in several pathological conditions. This study evaluated ADAMTS4 in leprosy skin lesions.

METHODS: In total, 519 skin samples were selected, including 20 healthy controls (HC) and 499 samples with leprosy skin lesions. Leprosy lesions were divided into tuberculoid range "T" (n=95), lepromatous range "L" (n=115), type 1 reaction (n=120), type 2 reaction (n=128), and lesions in regression (n=41). Following standardization with an anti-ADAMTS4 marker, all samples were subjected to immunohistochemistry (IHC). Marker expression in cells or tissues with moderate or intense staining intensity (2+ or 3+) was considered positive, and the absence of or weak expression (0 or 1+) was considered negative.

RESULTS: ADAMTS4 was expressed in several cells involved in the inflammatory processes of leprosy, particularly macrophages and fibroblasts, and in different skin tissues affected by leprosy lesions. Marker expression was remarkable in different tissues affected by leprosy lesions compared with the control group.

CONCLUSION: ADAMTS4 expression in different leprosy lesions and their reaction phenomena suggest its contribution to disease progression and reactive inflammatory amplification, indicating ADAMTS4 as a potential biomarker and therapeutic target in leprosy.

 a1699-5848